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Abstract 
We investigated the relative impacts of visceral adiposity and insulin resistance on the metabolic risk 
profile in middle-aged Japanese men. A cross-sectional study was conducted in 636 nondiabetic 
Japanese men with a mean age of 51.6 years. Visceral adipose tissue (AT) was assessed using 
computed tomography and insulin resistance was determined by the homeostasis model assessment 
insulin resistance (HOMA-IR). Metabolic risk factors were diagnosed according to the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III metabolic syndrome criteria: (1) 
hypertriglyceridemia, 2) low high-density-lipoprotein cholesterol, 3) hypertension, 4) impaired 
fasting glucose (IFG), and 5) impaired glucose tolerance (IGT). Visceral AT and HOMA-IR were 
significantly and positively correlated with each other (r=0.41, p<0.001). Using the 75th percentile 
value as a cut-point, those with isolated large visceral AT showed significantly greater odds ratios for 
each of the five risk factors measured except IFG, while those with isolated high HOMA-IR showed 
significantly greater odds ratios for each of the five risk factors except hypertriglyceridemia and 
IGT compared to the control group. The combined group (increased visceral AT and HOMA-IR) had 
the highest odds ratios for all studied risk factors. On logistic regression analysis using visceral AT 
and HOMA-IR as continuous independent variables, they were each independently associated with 
most of the metabolic risk factors and their clustering. In conclusion, neither visceral AT nor 
HOMA-IR stands out as the sole driving force of the risk profile; each makes a significant 
contribution to metabolic abnormalities in Japanese men. 
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1. Introduction 
Although there have been some controversies regarding the use of the term metabolic syndrome 
[1], even detractors agree that metabolic risk factors tend to cluster together in individuals [2]. Two 
main factors have been proposed to underlie this clustering: insulin resistance [3-6] and abdominal 
obesity [6-8]. Because insulin resistance is not easily measured in the outpatient setting and is 
significantly interrelated with abdominal obesity [9], a large waist girth has been adopted in recent 
criteria of metabolic syndrome [10, 11]. However, it has not been determined which of these is more 
fundamental for the clustering or how each contributes to specific metabolic risk factors. 
Asians, including the Japanese, develop metabolic disorders at a lower level of obesity than their 
Western counterparts [12]. This finding may be partly explained by the greater amounts of visceral 
adipose tissue (AT) in Asians than Europeans at any given level of body mass index [13, 14]. 
Visceral AT is supposed to play a unique role in the metabolic complications of obesity [15-18]. We 
recently reported that visceral AT, but not subcutaneous AT, was significantly associated with risk 
factor variations even after adjustments for body mass index and waist girth [19]. Thus, a direct 
measure of visceral AT would improve the accuracy of the associations between metabolic risk 
factors and obesity above anthropometric indices in the Japanese population. 
The aim of the present study was to investigate the relative contributions of visceral adiposity 
and insulin resistance to the metabolic risk profile in a relatively lean Japanese population. For that 
purpose, we cross-sectionally measured visceral AT using computed tomography (CT), and the 
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homeostasis model assessment insulin resistance (HOMA-IR), a widely used indicator for insulin 
resistance [20], in a large number of nondiabetic Japanese men. 
 
2. Methods 
2. 1. Study population 
Hokuriku Central Hospital has a special department where public school employees can receive 
routine medical checkups. Annual medical checkups are mandated by law and are sponsored by their 
mutual aid association. Of the 7,261 Japanese male employees who received a regular medical 
checkup between April 2006 and December 2008, 658 individuals voluntarily underwent both CT 
scanning to evaluate abdominal fat distribution and oral glucose tolerance test (OGTT). Of the 658 
participants, 22 were excluded due to elevated fasting plasma glucose (≥126mg/dl). The remaining 
636 participants were enrolled in the study. Each patient completed a questionnaire regarding current 
diseases and medications, alcohol consumption and smoking status. Participants were considered 
smokers if they smoked at least one cigarette per day. Alcohol use was assessed by the number of 
days per week of drinking regardless of quantity. Signed informed consent was obtained from all 
participants, and the hospital review board approved the study protocol. 
 
2. 2. Anthropometric measurements and blood sampling 
Anthropometric measurements were conducted according to published methods [21]. Blood 
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pressure was measured twice in the sitting position with an automatic device (Colin Model 
BP-203RV, Colin, Tokyo, Japan) after at least five minutes of rest. The average of the two readings 
was used for the blood pressure value.  
All participants were asked to visit our hospital between 8:00 a.m. and 9:00 a.m. after an 
overnight fast. Blood samples were drawn from the antecubital vein to measure total cholesterol, 
triglycerides, and high-density lipoprotein (HDL)-cholesterol. Then, OGTT (75 g dextrose 
monohydrate in 250 ml water) was performed with 0, 30, 60, and 120 min sampling to establish 
plasma glucose and insulin levels. Plasma glucose was assessed using the glucose oxidase method 
(Automatic Glucose Analyzer ADAMS Glucose GA-1160, Arkray, Kyoto). Triglycerides, total 
cholesterol, and HDL-cholesterol were measured using enzymatic analytical chemistry 
(Autoanalyzer BioMajesty JCA-BM1650, JEOL Ltd., Tokyo, Japan) at the hospital laboratory. 
Insulin concentration assays were performed by the chemiluminescence immunoassay method at a 
commercial laboratory (BML. Inc. Tokyo, Japan).  
 
2. 3. Assessment of HOMA-IR and metabolic risk factors 
Metabolic risk factors were defined according to the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III definition of metabolic syndrome [10]: 1) hypertriglyceridemia: 
≥150 mg/dl (1.69 mmol/l) or taking lipid-lowering medications; 2) low HDL-cholesterol: <40mg/dl 
(1.04mmol/l) or taking lipid-lowering medications; 3) high blood pressure: ≥130/85 mmHg or taking 
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anti-hypertensive medications; and 4) impaired fasting plasma glucose (IFG): ≥100mg/dl (5.6 
mmol/l) In addition, 5) impaired glucose tolerance (IGT) was defined as 2-hour post-challenge 
plasma glucose ≥140mg/dl (7.0 mmol/l). The HOMA-IR was calculated as follows: fasting plasma 
glucose (mmol/l) x fasting plasma insulin (μU/ml) / 22.5 [22]. 
 
2. 4. Measurement of abdominal adipose tissue by CT 
AT measurements were conducted using previously published methods [21]. Briefly, an axial CT 
scan at the level of the umbilicus was performed on each participant using an electron beam CT 
scanner (Aquilion Toshiba Medical Systems, Tokyo, Japan). Planimetric measurements at the level 
of the umbilicus have been well-correlated with volumetric quantifications of visceral AT (r=0.81, 
p<0.001) [23]. The images generated were analyzed using commercial software designed for the 
quantification of visceral AT (Fat Scan version 3.0, N2 System, Osaka, Japan). Correlation 
coefficients between two observers analyzing the same visceral AT image (n=30) were r=0.98 
(p<0.001).  
 
2. 5. Statistical analysis 
All analyses were conducted using SPSS software version 11.0 for Windows (SPSS Inc. 
Chicago, IL). Risk factor prevalence was plotted according to deciles of visceral AT and HOMA-IR. 
Tests for linear trends across deciles were performed by assigning the median value within each 
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category and treating the categories as a continuous variable. The participants were classified into 
four subgroups according to their visceral AT and HOMA-IR values using the 75th percentile as the 
cut-point. The control group consisted of those with both visceral AT and HOMA-IR below the 75th 
percentile. The isolated large visceral AT group was those with visceral AT above the 75th percentile 
but HOMA-IR below the 75th percentile. The isolated high HOMA-IR group was those with 
HOMA-IR above the 75th percentile but visceral AT below the 75th percentile. The combined group 
was those with both visceral AT and HOMA-IR above the 75th percentile values. Adjusted odds 
ratios for each metabolic risk factor in each group relative to the control group were calculated using 
binary logistic regression. The following variables were used as covariates in the regression 
analyses: age, alcohol use (<1 day per week, 1-6 days per week, or daily use), and cigarette smoking 
(currently smoking or not). The independent associations of visceral AT and HOMA-IR as 
continuous variables were also assessed using logistic regression analysis. Visceral AT and 
HOMA-IR were first standardized to a mean of 0 and standard deviation of 1, and then included in 
the models with the covariates mentioned above. The significance of the interactions were examined 
using interaction terms (visceral AT * HOMA-IR) in the logistic regression model. The triglyceride 
and HOMA-IR values were log-transformed prior to analysis due to their skewed distribution. A p 
value of <0.05 was considered statistically significant.  
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3. Results 
Table 1 shows the clinical characteristics of the participants. The mean age was approximately 
50 years and the mean body mass index was approximately 25 kg/m2. Although all participants were 
apparently healthy and engaging in full-time work, approximately half were hypertensive, more than 
one quarter had either IFG or IGT, and 39.0% had hypertriglyceridemia. 
Figure 1 shows the prevalence of hypertension, IFG, IGT, hypertriglyceridemia, low 
HDL-cholesterol, and the clustering of two or more risk factors across deciles of visceral AT (A) and 
HOMA-IR (B). Increased levels of both visceral AT and HOMA-IR were significantly associated 
with increases in all risk factors (p<0.05). 
Visceral AT and HOMA-IR were significantly and positively correlated with each other (r=0.41, 
p<0.001). The participants were classified into four groups according to the 75th percentile values, 
and the odds ratios for individual risk factors in each group compared to the control group were 
calculated (Table 2). Those with isolated large visceral AT had significantly greater odds ratios for 
each of the five risk factors measured except IFG, while those with isolated high HOMA-IR had 
significantly greater odds ratios for each of the five risk factors except hypertriglyceridemia and IGT 
compared to the control group. Both those with isolated large visceral AT and high HOMA-IR 
showed greater odds ratios for the clustering of two or more risk factors compared to the control 
group. The combined group (both large visceral AT and high HOMA-IR) had the highest odds ratios 
for all the five risk factors and their clustering. 
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Table 3 shows the results of logistic regression analysis using visceral AT and HOMA-IR as 
continuous independent variables for each metabolic risk factor. Increased visceral AT, independent 
of HOMA-IR, was significantly associated with each of the five risk factors except IFG, while 
increased HOMA-IR was independently associated with each of the five risk factors except 
low-HDL-cholesterol and IGT. Both visceral AT and HOMA-IR were independently associated with 
the clustering of two or more risk factors. There was a significant negative interaction between 
visceral AT and HOMA-IR for hypertriglyceridemia (p=0.003), indicating that its odds ratio 
associated with increasing visceral AT and HOMA-IR was attenuated at higher levels. 
The same analyses were conducted after substituting fasting insulin levels for HOMA-IR 
(supplementary data). When participants were classified by fasting insulin levels, group comparisons 
showed similar patterns of association with metabolic risk factors as HOMA-IR. In the logistic 
regression analysis, the association of fasting insulin with IFG was attenuated compared to that of 
HOMA-IR, but was still significant (p<0.001).  
 
4. Discussion 
This cross-sectional study demonstrated that increased visceral AT and HOMA-IR were each 
independently associated with most metabolic risk factors and their clustering, although their 
respective contributions varied among risk factors. Visceral AT and HOMA-IR were indeed 
correlated with each other in this relatively lean Japanese population, but the large sample size of 
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this study allowed to evaluate the independent relationships of these intersected conditions with 
metabolic risk factors. 
Visceral AT and HOMA-IR showed a significant correlation with each other, which is in 
agreement with prior studies in other populations. Previously reported correlation coefficients 
between directly measured visceral AT and HOMA-IR were 0.40 in Japanese men with normal 
glucose tolerance [15]; 0.34 in black and 0.44 in white men [24]; and 0.28 in healthy Koreans [25]. 
However, when using the top quartile of visceral AT and HOMA-IR in group comparisons, the 
overlap between these two conditions was about 50%; the remaining half had each condition in 
isolation. Obesity can be dissociated from HOMA-IR even when evaluated by visceral AT.  
Hypertriglyceridemia was associated independently both with visceral AT and HOMA-IR by 
logistic regression analysis. Prior studies using a more sophisticated method to assess insulin 
resistance revealed a major contribution of visceral AT but an additional independent contribution of 
insulin resistance to triglyceride concentrations in nondiabetic subjects [26] [27]. Conversely, Piche 
et al. reported that women with large visceral AT but low insulin resistance showed similar 
triglyceride concentrations to control subjects, and visceral AT accumulation was associated with 
hypertriglyceridemia only in the presence of insulin resistance [28]. This inconsistency may be 
attributed to the inclusion of diabetic subjects in the latter study. In this study, the odds ratio of 
hypertriglyceridemia was not significantly different between the isolated high HOMA-IR group and 
the control group. Theoretically, the reduced anti-lipolytic action of insulin generates an increase in 
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circulating free fatty acids (FFAs) which can flux to the liver and stimulate triglyceride formation 
[29, 30]. 
The contribution of visceral AT and HOMA-IR varied between IFG and IGT. Because fasting 
plasma glucose is part of HOMA-IR, the analysis was repeated substituting HOMA-IR with fasting 
insulin concentrations. The results were similar, showing a dominant association between IFG and 
fasting insulin and between IGT and visceral AT. These results confirm the notion that IFG and IGT 
may have different pathophysiological origins. IFG is primarily caused by hepatic insulin resistance 
in a fasted state, whereas IGT is caused by peripheral (muscle) insulin resistance followed by a 
decline in beta-cell function in a fed state [31, 32]. 
For almost all risk factors, the odds ratios were highest in those with both visceral AT and 
HOMA-IR above the 75th percentile. This was particularly pronounced for clustering of two or more 
risk factors. However, even in this instance, the interaction between visceral AT and HOMA-IR was 
not significant, indicating that their effects are additive, not multiplicative. Notably, a negative 
interaction between visceral AT and HOMA-IR was found with respect to hypertriglyceridemia. This 
may be due to a threshold effect, whereby hypertriglyceridemia prevalence is already so high that 
increased HOMA-IR is not associated with further increases in its prevalence. 
    Metabolic responses to fat accumulation have been reported to differ by ethnicity. 
African-Americans have higher HOMA-IR or fasting insulin values and lower serum triglyceride 
concentrations than Caucasians even after controlling for visceral AT [33, 34]. Conversely, Asians 
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reportedly have significantly lower HOMA-IR values compared to Caucasians even after accounting 
for body mass index [35] and for liver fat content [36]. In the present study, HOMA-IR 
independently contributed to metabolic risk factors, although it should be noted that the absolute 
level of HOMA-IR in Japanese populations would be much lower compared to Western populations. 
Several limitations of this study should be considered. First, HOMA-IR is an indirect measure 
of insulin resistance, which is assumed to reflect mainly hepatic insulin resistance in the basal state 
[37]. However, studies using a direct measure such as euglycemic-hyperinsulinemic clamp [38] or 
intravenous glucose tolerance [39] have reported that metabolic syndrome risk factor patterns were 
similar when HOMA-IR was used in place of these direct measures. Second, participants were 
recruited from a population engaging in a specific profession, not from a community-based sample. 
The role of the “healthy worker effect” should also be considered when generalizing these results to 
other populations. Third, the reproducibility of the measurements of visceral AT by CT scanning still 
seems to be incomplete due to the effects of respiratory and peristaltic movements of the patients. 
Nonetheless, a single planimetric measurement of visceral AT has shown good correlation with 
volumetric quantifications [23]. Fourth, we did not measure sex hormones, which have been 
proposed to underlie the expression of the metabolic abnormalities and might have confounded the 
associations of visceral AT and HOMA-IR with risk factors [40, 41]. Finally, the cross-sectional 
design is unable to determine the causal or temporal sequence among visceral AT, HOMA-IR, and 
metabolic risk factors. 
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In conclusion, neither visceral AT nor HOMA-IR stands out as the sole driving force of the 
metabolic syndrome profile, as each contributed significantly to various metabolic abnormalities. 
Those with a combination of large visceral AT and high HOMA-IR had the highest odds ratios for 
the individual risk factors and their clustering. Further longitudinal studies are needed to investigate 
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Age (years) 51.6 ± 7.1
Height (cm) 170.0 ± 5.8
Weight (kg) 73.3 ± 10.2
Body mass index (kg/m2) 25.3 ± 2.9
Waist circumference (cm) 87.9 ± 7.5
Systolic BP (mmHg) 130.5 ± 15.2
Diastolic BP (mmHg) 81.5 ± 9.5
Total-cholesterol (mg/dl) 212.3 ± 36.4
Triglycerides (mg/dl) 91/122/174
HDL-cholesterol (mg/dl) 54.3 ± 12.0
Fasting plasma gulcose (mg/dl) 99.2 ± 9.2
2-hour plasma gulcose (mg/dl) 123.5 ± 32.4
Fasting insulin (mg/dl) 3.2/4.4/6.1
HOMA-IR 0.79/1.07/1.51
    Visceral  AT (cm2) 140.9 ± 50.7
    Hypertensiona (%) 55.7
    Hypertriglyceridemiab (%) 39.0
    Low HDL-cholesterolc (%) 10.1
    Impaired fasting glucosed (%) 43.2
    Impaired glucose tolerancee (%) 26.3
    Two or more risk factors (%) 51.3
Current cigarette smoker (%) 22.3
    Alcohol use (%)
  drinking everyday 33.8
  drinking 1-6 days per week 39.6
Table 1 Clinical characteristics of the study participants
Data are mean ± SD,  25/50/75th percentile values, or %. BP, blood
pressure; AT, adipose tissue; HDL, high-density lipoprotein.
adefined by systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg;
bdefined by ≥150 mg/dl; cdefined by  <40 mg/dl.dFasting glucose ≥










Group 1 Group 2 Group 3 Group 4
n=392 n=85 n=85 n=74
Hypertension 1.00 2.0 (1.2-3.3) 2.0 (1.2-3.2) 5.9 (3.0-11.3)
Hypertriglyceridemia 1.00 2.6 (1.6-4.3) 1.5 (0.9-2.5) 3.4 (2.0-5.7)
Low HDL-C 1.00 2.8 (1.4-5.8) 2.5 (1.2-5.2) 2.9 (1.4-6.2)
Impaired fasting glucose 1.00 1.2 (0.7-1.9) 3.4 (2.1-5.7) 5.9 (3.3-10.5)
Impaired glucose toleranc 1.00 1.8 (1.0-3.0) 1.2 (0.7-2.2) 2.9 (1.7-4.9)
Two or more risk factors 1.00 3.2 (2.0-5.3) 3.8 (2.3-6.4) 14.0 (6.5-30.1)
Table 2 Adjusteda odds ratios for the presence of metabolic risk factors according
to viscear adipose tissue (AT) and HOMA-IR status
control, both visceral AT and HOMA-IR are below their 75th percentiles; isolated large visceral AT,
visceral AT is above 75th percentile but HOMA-IR is below 75th percentile; isolated high HOMA-IR,
HOMA-IR is above 75th percentile but visceral AT is below 75th percentile; combined, both visceral AT
and HOMA-IR are above their 75th percentiles. aadjusted for age, smoking status, and alcohol consumption.
Significantly higher odds ratios compared to the control group are shown in bold letters.























Odds ratio p value p forinteraction
visceral AT 1.69 (1.39-2.06) <0.001
HOMA-IR 1.26 (1.04-1.53) 0.017
visceral AT 1.68 (1.37-2.05) <0.001
HOMA-IR 1.34 (1.10-1.63) 0.004
visceral AT 1.68 (1.25-2.24) <0.001
HOMA-IR 1.17 (0.86-1.58) 0.327
visceral AT 1.07 (0.89-1.30) 0.463
HOMA-IR 2.17 (1.74-2.71) <0.001
visceral AT 1.49 (1.21-1.83) <0.001
HOMA-IR 1.15 (0.93-1.42) 0.199
visceral AT 1.94 (1.57-2.41) <0.001





aadjusted for age, smoking status, and alcohol consumption. Data presented the change in odds of having




0.128Two or more risk
factors
Table 3 Adjusteda odds ratios for having metabolic risk factors with 1 SD
increase in visceral adipose tissue (AT) and HOMA-IR as continuous variables.
0.142
0.003
0.116
Hypertension
Hypertriglyceridemia
Low HDL-C
 
 
 
 
 
 
